Venetoclax, azacitidine, combined with low-dose cytarabine in treatment-naive, elderly or unfit patients with acute myeloid leukemia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063804

Enrollment

Unknown

Registered

2022-09-16

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute meyloid leukemia

Interventions

exprerimental group:Venetoclax, azacitidine, combined with low-dose cytarabine

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. The patient fully understands this study and voluntarily participates and signs an Informed Consent Form (ICF); 2. Patients diagnosed with adult acute myeloid leukemia; 3. Elderly patients aged 60 to 90 years (including threshold), patients aged6); 4. ECOG score3 months.

Exclusion criteria

Exclusion criteria: 1. Under 60 years old who can accept standard dose or intensive chemotherapy; 2. Can not come back for eximination on time; 3. Unsuitable subjects for this study determined by the investigator.

Design outcomes

Primary

Measure	Time frame
Rate of MRD negativity;	—

Secondary

Measure	Time frame
complete remission(CR);Objective Response Rate (ORR);1 years overall survival;2 year Progression-Free-Survival(PFS);Advert effect;	—

Countries

China

Contacts

Public ContactHan Xiao

Second Affiliated Hospital, Army Medical University

zxiao2@126.com+86 18189596376

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026